Literature DB >> 3089683

Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.

I el-Raghy, D J Back, M Makeram, H Salem, F Osman, M Fathalla, M L Orme.   

Abstract

Plasma concentration profiles and pharmacokinetic parameters have been obtained following single dose administration of three commonly used oral contraceptive steroid preparations, Ovral, Nordette and Norminest to Egyptian women. The constituents of the preparations are as follows: Ovral (50 micrograms ethinyloestradiol, EE2 and 500 micrograms levonorgestrel, LNG); Nordette (30 micrograms EE2 and 150 micrograms LNG); and Norminest (35 micrograms EE2 and 500 micrograms norethisterone, NOR). Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette. There was no significant difference in half-life (t1/2), oral clearance (CL) or apparent volume of distribution (Vd). The relative values of the area under the plasma concentration-time curve (AUC) reflected well the different amounts of oestrogen in each preparation. There was no significant difference in t1/2, CL or Vd for LNG in the 2 preparations containing this progestogen. The mean AUC following Nordette (150 micrograms LNG) was 40% of that following Ovral (500 micrograms LNG; p less than 0.001). Comparing pharmacokinetic parameters for the same dose of LNG (Ovral) and NOR (Norminest) showed the AUC to be decreased and CL and Vd increased in the latter group. The study indicates that the kinetic profile of the OCS in healthy Egyptian women are similar to other ethnic populations.

Entities:  

Keywords:  Africa; Arab Countries; Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen--analysis; Contraceptive Agents, Female; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--analysis; Contraceptive Methods--administraction and dosage; Contraceptive Methods--pharmacodynamics; Developing Countries; Egypt; Endocrine System; Ethinyl Estradiol--analysis; Examinations And Diagnoses; Family Planning; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Levonorgestrel--analysis; Mediterranean Countries; Norethindrone--analysis; Northern Africa; Oral Contraceptives--administraction and dosage; Oral Contraceptives--pharmacodynamics; Physiology; Reproductive Control Agents

Mesh:

Substances:

Year:  1986        PMID: 3089683     DOI: 10.1016/0010-7824(86)90100-9

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

Review 1.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

2.  Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women.

Authors:  Hartmut Blode; Kristin Kowal; Katrin Roth; Stefanie Reif
Journal:  Eur J Contracept Reprod Health Care       Date:  2012-06-10       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.